Heparin Sodium Rovi (Heparin Sodium)

Heparin Sodium Rovi is indicated for the prevention and treatment of several thromboembolic disorders where rapid anticoagulation is required.

• Prevention of deep‑vein thrombosis (DVT) in patients undergoing surgery or immobilization.
• Treatment of acute pulmonary embolism to reduce clot burden.
• Management of unstable angina or non‑ST elevation myocardial infarction as an adjunct to other antiplatelet agents.
• Anticoagulation during hemodialysis or extracorporeal circulation procedures.
• Prophylaxis of clot formation in patients with atrial fibrillation who are not candidates for oral anticoagulants.

Adverse reactions to Heparin Sodium Rovi vary in frequency and severity; they are categorized as common or serious.

Common

• Minor bleeding at the injection site or easy bruising.
• Nausea, vomiting, or mild abdominal discomfort.
• Transient elevation of liver enzymes.
• Localized skin redness or itching.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count.
• Allergic anaphylaxis presenting with hives, swelling, or respiratory distress.

Before initiating Heparin Sodium Rovi, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess baseline coagulation parameters (aPTT, platelet count) and renal function.
• Use lower initial doses in patients with a history of bleeding or recent surgery.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Monitor for signs of heparin‑induced thrombocytopenia during the first 5–10 days of therapy.
• Adjust dosing in pregnant or lactating patients only after risk‑benefit assessment.
• Consider alternative anticoagulants in patients with severe liver disease.

Heparin Sodium Rovi may interact with other medications that affect hemostasis or drug metabolism; awareness of these interactions helps prevent adverse events.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) that increase bleeding risk.
• Administration together with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs.
• Combination with fibrinolytic therapy (e.g., alteplase) due to additive hemorrhagic potential.

Use with caution

• Concomitant use of drugs that depress platelet function, like thienopyridines, may require closer monitoring.
• Concurrent administration of certain antibiotics (e.g., vancomycin) that can potentiate thrombocytopenia.
• Use with high‑dose corticosteroids may increase gastrointestinal bleeding risk.